- Ernexa Therapeutics (ERNA, Financial) to present new data on ovarian cancer treatment at AACR Annual Meeting 2025.
- ERNA-101, engineered cell therapy, aimed at reshaping tumor microenvironment to boost anti-tumor immunity.
- Study led by Dr. Michael Andreeff of MD Anderson Cancer Center, highlighting potential new hope for advanced ovarian cancer patients.
Ernexa Therapeutics (NASDAQ: ERNA) has announced that it will unveil new findings at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentation, scheduled for Monday, April 28, 2025, from 2:00-5:00 pm CDT in Poster Section 37, will feature their groundbreaking cell therapy product, ERNA-101.
Developed to address the challenging treatment landscape of ovarian cancer, ERNA-101 uses specially engineered cells to deliver therapy directly to tumors. This innovative approach involves the secretion of immune-stimulating cytokines, aiming to modify the tumor microenvironment and enhance the body's anti-tumor immune responses. The study, spearheaded by Dr. Michael Andreeff of the renowned MD Anderson Cancer Center, seeks to offer new treatment possibilities for patients with limited options.
Sanjeev Luther, President and CEO of Ernexa Therapeutics, highlighted the significance of ERNA-101, emphasizing its potential to transform cell therapy's future by engaging the immune system against hard-to-treat cancers. Conference attendees will have the opportunity to engage with Ernexa's Chief Scientific Officer, Robert Pierce, M.D., and the research team, gaining deeper insights into ERNA-101's promising capabilities.
For those interested in exploring further details regarding Ernexa Therapeutics and their pioneering work, please visit their official website at www.ernexatx.com.
